CLINICAL_TRIALS
trial_result
· 2014-12-19
Clinical Trial Update: Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer [Phase 2]
Summary
A Phase 2 trial of Nexavar (sorafenib) in patients with advanced renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED